Sign up to all DiabetesontheNet journals
Journals
Sign up to all DiabetesontheNet journals
By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
Diabetes &
Primary Care
Issue:
Vol:23 | No:04
Diabetes Distilled: Missed opportunities: Statins underprescribed in ethnic minorities
People of South Asian and African/African Caribbean ethnicity are three times more likely to develop type 2 diabetes and are more at risk from CV complications compared to those of European ethnicity in the UK, with African/African Caribbean people at increased stroke risk independent of cholesterol levels. Lowering cholesterol with statin therapy for primary prevention is effective in reducing the burden of CV disease across ethnic groups, but previous UK studies identified ethnic differences in prescribing. This observational cohort study used the Clinical Practice Research Datalink (CPRD) to identify 31,000 people, between January 2006 and June 2019, who were newly diagnosed with type 2 diabetes and did not have ASCVD, and who were not already taking a statin but met the NICE guideline recommendations for statin prescribing for primary prevention (Eastwood et al, 2021). According to self-defined and Read-coded ethnicity, 88% of the cohort were European ethnicity, 8% South Asian and 4% African/African Caribbean ethnicity, reflecting the age and ethnic mix of the UK population.
Using age- and gender-adjusted models, people of African/African Caribbean ethnicity meeting the guideline recommendations for statin initiation were one third less likely to have them prescribed and South Asians were 12% less likely, compared to those of European ethnicity. The cholesterol to high-density lipoprotein ratio slightly attenuated the differences between ethnic groups, but there was no significant impact when adjustment for CV risk factors, demographic factors, deprivation, comorbidity, healthcare usage and polypharmacy were explored. After all adjustments, compared to people of European ethnicity newly diagnosed with type 2 diabetes and meeting guideline recommendations for statin therapy, African/African Caribbean people remained 24% less likely to be prescribed statins and South Asians 9% less likely. The authors concluded that they were unable to fully account for the prescribing differences. Lower baseline cholesterol in the South Asian and African/African Caribbean groups may have influenced those who prescribed based on cholesterol alone.
It was calculated that equalising statin initiation across these three ethnic groups could prevent around 12,600 ASCVD events in people currently living with a diagnosis of type 2 diabetes. The authors call for further research to confirm their findings, to further evaluate possible reasons for the prescribing differences and to provide education to equalise statin prescribing across ethnic groups, and thus contribute to reducing ASCVD events.
Strengths of the study included access to a large, nationally representative population with individual-level prescribing data and accounting for changes in the NICE statin guideline recommendations in force when assessing eligibility for the cohort.
Click here to read the study in full.
Eastwood SV, Mathur R, Sattar N et al (2021) Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006–2019: A cohort study.” PLoS Med 18: e1003672
Rolling out tirzepatide for weight management: NHS England recommendations
Diabetes Distilled: Heart and SOUL – oral semaglutide demonstrates cardiovascular benefit in high-risk people with type 2 diabetes
NICE overweight and obesity guidelines – what’s new?
PCDO Society National Conference 2025: Request for poster abstracts
Diabetes Distilled: Time to intensify blood pressure treatment in people with type 2 diabetes?
How to undertake a multiple long-term conditions review
Diabetes Distilled: Preserving muscle is important when using incretin mimetics for weight loss
Satish Durgam reviews who will be eligible to receive tirzpepatide for weight management and when.
24 Apr 2025
Results of SOUL trial suggest oral semaglutide offers similar cardiovascular benefits to the injectable formulation.
22 Apr 2025
The new NG246 guideline replaces several pre-existing NICE obesity guidelines. Sally Erskine reviews the key changes.
15 Apr 2025
Poster abstract submissions are invited for the 21st National Conference of the PCDO Society, which will be held on 19 and 20 November.
10 Apr 2025